OPTIMIZING MIFEPRISTONE LEVELS FOR CUSHING'S PATENTS

• US 20160310507A1
• Filed: 04/20/2016
• Published: 10/27/2016
• Est. Priority Date: 04/21/2015
• Status: Active Grant

• Current Assignee: Corcept Therapeutics, Corcept Therapeutics Inc.
• Original Assignee: Corcept Therapeutics Inc.
• Inventors: Gross, Coleman, Belanoff, Joseph
• Granted Patent: US 9,943,526 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/136 having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• CPC Class Codes: A61K 31/567 substituted in position 17 alpha, e.g. mestranol, norethandrolone
• CPC Class Codes: G01N 2800/048 Pituitary or hypothalamic - pituitary relationships, e.g. vasopressin or ADH related
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/94 involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Abstract

The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing'"'"'s syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.

Claims

1. A method for improving efficacy of mifepristone treatment in a patient suffering from Cushing'"'"'s syndrome, the method comprising:

treating the patient with seven or more daily doses of mifepristone over a period of seven or more days;

testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and

adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL,

with the proviso that the patient is not already suffering from a condition indicated for treatment with mifepristone, thereby improving the efficacy of mifepristone treatment for the patient suffering from Cushing'"'"'s syndrome.

2. The method of claim 1, wherein each of the seven or more daily doses of mifepristone are administered orally.

3. The method of claim 1, wherein the daily dose is at least 300 mg.

4. The method of claim 1, wherein the daily dose is at least 600 mg.

5. The method of claim 1, wherein the daily dose is at least 900 mg.

6. The method of claim 1, wherein the daily dose is at least 1200 mg.

7. The method of claim 1, wherein the patient is treated with 28 or more daily doses over a period of 28 or more days.

8. The method of claim 1, wherein the testing is performed by a plasma sampling collection device suitable for detecting mifepristone serum levels.

9. The method of claim 1, wherein the adjusting step comprises increasing the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.